Precision Cancer Therapy in Rare Cancers
The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers
Oslo University Hospital
96 participants
Mar 20, 2025
INTERVENTIONAL
Conditions
Summary
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
imatinib treatment based on molecular alterations
According to biomarkers
According to biomarkers
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06119789